Provided by Tiger Trade Technology Pte. Ltd.

Perspective Therapeutics

2.73
-0.1900-6.51%
Post-market: 2.730.00000.00%16:10 EDT
Volume:1.47M
Turnover:4.00M
Market Cap:311.22M
PE:-2.05
High:2.89
Open:2.88
Low:2.66
Close:2.92
52wk High:6.16
52wk Low:1.96
Shares:114.00M
Float Shares:68.28M
Volume Ratio:0.90
T/O Rate:2.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3300
EPS(LYR):-1.3971
ROE:-39.57%
ROA:-22.28%
PB:0.96
PE(LYR):-1.95

Loading ...

Perspective Therapeutics Q2 EPS $(0.22) Beats $(0.26) Estimate, Sales $81.000K Miss $83.154K Estimate

Benzinga Earnings
·
Aug 11

Perspective Therapeutics Q2 EPS USD -0.22

Reuters
·
Aug 11

Perspective Therapeutics Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 11

Perspective Therapeutics Q2 Net Income from Cont Ops USD -26.983 Million

THOMSON REUTERS
·
Aug 11

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results

THOMSON REUTERS
·
Aug 11

Perspective Therapeutics Advances 212Pb Radiopharmaceutical Oncology Platform

TIPRANKS
·
Aug 04

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results

GlobeNewswire
·
Jul 31

Perspective Therapeutics' Neuroendocrine Tumor Therapy Receives EU Orphan Drug Designation

MT Newswires Live
·
Jul 28

Perspective Therapeutics Wins EU Orphan Drug Status for [212Pb]VMT-α-NET in GEP-NETs

Reuters
·
Jul 28

Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212PB]Vmt-Α-Net in Gep-Nets

THOMSON REUTERS
·
Jul 28

Perspective Therapeutics Announces Acceptance of Vmt-α-net Data for Oral Presentation at the Esmo Congress 2026

THOMSON REUTERS
·
Jul 18

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026

GlobeNewswire
·
Jul 18

Perspective Therapeutics management to meet virtually with BTIG

TIPRANKS
·
Jul 11

Perspective Therapeutics Names Paul Lyne Chief Science Officer as Co-founder Schultz Moves to Advisor Role

Reuters
·
Jul 08

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Tenaya Therapeutics (TNYA)

TIPRANKS
·
Jul 06

Perspective Therapeutics Highlights Progress in Alpha Radiopharmaceutical Pipeline

TIPRANKS
·
Jul 02

Perspective Therapeutics management to meet virtually with BTIG

TIPRANKS
·
Jun 27

Perspective Therapeutics doses first meningioma patient in Phase 1/2a trial of [212Pb]VMT-α-NET

Reuters
·
Jun 03

Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed With [212PB]Vmt-Α-Net in the Meningioma Cohort of a Phase 1/2a Study

THOMSON REUTERS
·
Jun 03

Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study

GlobeNewswire
·
Jun 03